Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Outlook 2025 – Insights for Executive and Strategic Planning
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Grown from 2024 to 2025?
The market size for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) has experienced swift expansion in the past few years. It’s projected to increase from $5.35 billion in 2024 to $6.09 billion in 2025, with a compound annual growth rate (CAGR) of 13.8%. The escalation in the historical timeframe is due to several factors, such as the rising occurrence of neurological disorders and chronic pain conditions, heightened awareness of the disease, a surge in cases of paroxysmal nocturnal hemoglobinuria (PNH), increased consciousness about unusual hematological disorders, and an upswing in regulatory approvals along with research and development (R&D) activities.
What Growth Rate Is Anticipated for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market in the Coming Years?
In the coming years, the market size for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) is predicted to experience swift expansion, reaching $10.09 billion in 2029, with a compound annual growth rate (CAGR) of 13.5%. This growth projection is based on factors including a rising occurrence of rare diseases, growth in healthcare spending and deeper access to progressive therapies, increased investment in healthcare facilities, a surge in home-based tests and remote monitoring, and accelerated research and development activities. Significant trends that are projected for the forecast period are advancements in genetic testing and biomarkers, therapeutic progression, the emergence of targeted therapies, biotechnological advances, and the creation of innovative treatments.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23469&type=smp
Who Are the Leading Companies in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market are F. Hoffmann-La Roche Ltd, AstraZeneca PLC, Novartis AG, Amgen Inc., Mayo Clinic, Regeneron Pharmaceuticals, Cleveland Clinic Foundation, Johns Hopkins Medicine, Memorial Sloan Kettering Cancer Center, Stanford Health Care, University of California San Francisco (UCSF) Health, Emory Healthcare, Cedars-Sinai Medical Center, Duke University Health System, Mount Sinai Health System, Dana-Farber Cancer Institute, Swedish Orphan Biovitrum, Alnylam Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceuticals
What Are the Key Drivers of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
As hematologic disorders become more prevalent, the paroxysmal nocturnal hemoglobinuria (PNH) treatment market is anticipated to experience growth. Hematologic disorders encompass a wide array of medical issues affecting blood and associated organs, including irregularities in red and white blood cells, platelets, bone marrow, and the clotting system. This can result in various health complications like anemia, clotting irregularities, and cancers. Aspects such as aging populations and genetic predispositions are contributing to the rise of these blood-related disorders, with genetic aberrations playing a pivotal role as they can initiate the production of abnormal blood cells, leading to varied hematologic health issues. PNH treatment effectively manages these disorders by providing specially designed therapies that lessen complement-mediated hemolysis, decrease thrombotic complications, and improve patient survival rates. In fact, Cancer Research UK, a charity organization headquartered in the UK, projected in July 2024 that there will be an upswing in new leukemia cases (a hematologic condition), with expected cases to rise from roughly 12,400 between 2023-2025 to about 14,500 by the years 2038-2040. Hence, the surge in hematologic disorders is propelling the growth of the paroxysmal nocturnal hemoglobinuria (PNH) treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23469&type=smp
What Are the Key Market Segments in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry?
The paroxysmal nocturnal hemoglobinuria (PNH) treatment market covered in this report is segmented –
1) By Treatment Type: Complement C5 Inhibitors, Anti-Complement Component 5a Receptor (C5aR) Monoclonal Antibodies, Alternative Pathway Inhibitors, Hematopoietic Stem Cell Transplantation, Other Therapies
2) By Route Of Administration: Intravenous, Subcutaneous, Oral
3) By market Availability: Approved, In Pipeline, Investigational
4) By End-Use: Hospitals, Specialty Clinics, Homecare Settings, Other End-Users
Subsegments:
1) By Complement : C5 InhibitorsEculizumab (Soliris), Ravulizumab (Ultomiris), Emerging C5 Inhibitors, Biosimilars Of C5 Inhibitors,
2) By Anti-Complement Component 5a Receptor Monoclonal Antibodies: Avacopan (Tavneos), Other Investigational C5aR mAbs, Monotherapy vs Combination Therapy, Clinical Trial Phase (Phase I, II, III)
3) By Alternative Pathway Inhibitors: C3 Inhibitors, Factor B Inhibitors, Factor D Inhibitors, Targeting Complement Amplification, Combination Therapies And Dual Inhibition
4) By Hematopoietic Stem Cell Transplantation (HSCT) : Autologous HSCT vs. Allogeneic HSCT, Pre-Transplant Conditioning Therapies, Post-Transplant Immunosuppressive Therapies
5) By Other Therapies: Immunosuppressive Therapy, Supportive Care, Anticoagulation Therapy, Gene Therapy
What Are the Latest Trends in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
Leading companies in the field of PNH treatment are increasingly concentrating on developing innovative therapies, such as oral factor B inhibitors, providing a new treatment alternative that improves both the effectiveness and the patient comfort in dealing with PNH. An oral Factor B inhibitor is a specially formulated medication that selectively blocks Factor B in the alternative complement pathway with the goal of managing excessive immune system activity and reducing inflammation in diseases caused by the complement system. For example, in December 2023, Novartis AG, a pharmaceutical firm based in Switzerland, proclaimed the approval of Fabhalta (iptacopan) by the FDA, marking its introduction as the initial oral monotherapy for PNH treatment. This ground-breaking Factor B inhibitor offers a more inclusive technique towards managing complement-mediated hemolysis by intervening in the alternative complement pathway sooner, this leads to improved hemoglobin levels and less dependency on blood transfusions. Fabhalta’s approval signifies a monumental step forward in PNH treatment as it offers heightened effectiveness, improved acceptance by patients, and an alternative to intravenous therapies, altogether revolutionizing the therapeutic regimen for this rare hematologic disorder.
Access The Full Report Here:
What Are the Key Regional Markets in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23469
This Report Delivers Insight On:
1. How big is the paroxysmal nocturnal hemoglobinuria (pnh) treatment market, and how is it changing globally?
2. Who are the major companies in the paroxysmal nocturnal hemoglobinuria (pnh) treatment market, and how are they performing?
3. What are the key opportunities and risks in the paroxysmal nocturnal hemoglobinuria (pnh) treatment market right now?
4. Which products or customer segments are growing the most in the paroxysmal nocturnal hemoglobinuria (pnh) treatment market?
5. What factors are helping or slowing down the growth of the paroxysmal nocturnal hemoglobinuria (pnh) treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
